Why Is Alumis Stock Falling Tuesday?
Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.
Share
Why It Matters
Alumis tested a medicine for a disease called lupus, but it didn't work as well as they hoped in most patients—though it helped some groups better. When medicine tests disappoint, people worry less about the company's future, so the stock price falls.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.